Kemwell Biopharma's Bengaluru Facility Receives FDA Approval for Commercial Biologics Manufacturing
Key Insights
Kemwell Biopharma (search)'s drug-product manufacturing facility in Bengaluru has successfully completed a U.S. FDA pre-approval inspection and is now cleared for commercial manufacturing of injectable products for the U.S. market.
This milestone marks the first product to receive U.S. FDA clearance for commercial supply from Kemwell's Bengaluru facility since it became a dedicated biologics campus eight years ago.
The approval follows a product technology transfer from Cipla Limited and demonstrates Kemwell's ability to meet stringent cGMP and aseptic drug-product manufacturing standards.
Kemwell Biopharma (search) Pvt Ltd, a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (search) (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market.
This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell's Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. The achievement demonstrates the company's ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards.
Strategic Partnership with Cipla
The inspection was conducted as part of a Pre-Approval Inspection (PAI) following a product technology transfer from Cipla Limited, a leading global pharmaceutical company. The outcome underscores the confidence that major pharmaceutical innovators place in Kemwell's capabilities and the reliability of its manufacturing network.
"Our partnership with Kemwell aligns with Cipla's strategy of building a resilient and globally trusted supply chain," said Pradeep Bhadauria, Chief Scientific Officer, Cipla Limited. "The successful completion of the FDA inspection at Kemwell's Bengaluru site reinforces our commitment to delivering safe, high-quality medicines to patients in regulated markets."
Advanced Manufacturing Capabilities
Kemwell's FDA-approved site features advanced single-use and stainless-steel bioreactors, with over 5000L+ of installed upstream capacity, commercial fill-finish lines for liquid and lyophilized vials, and pre-filled syringe systems equipped with isolator technology for enhanced sterility assurance. In addition to drug-product (DP) manufacturing, the site supports process development, analytical testing, and drug-substance (DS) production—enabling fully integrated biologics programs from cell-line to commercial supply.
The company's services span a wide spectrum of biologic modalities—including Monoclonal Antibodies (search), recombinant proteins (search), bispecific and trispecific antibodies (search), biosimilars (search) and New Biological Entities—and extend to advanced therapies with cGMP cell-therapy development and manufacturing capabilities.
Industry Impact and Future Outlook
"Achieving FDA clearance for commercial manufacturing from our Bengaluru site marks a defining moment in Kemwell's growth journey," said Anurag Bagaria, Chairman and CEO, Kemwell Biopharma (search). "It reflects our team's steadfast focus on quality, compliance, and scientific excellence. We are proud to support our partners in accelerating the delivery of important therapies to patients in the United States and around the world."
This achievement further strengthens Kemwell's strategy to expand capacity, invest in advanced manufacturing technologies, and deliver compliant, scalable solutions that meet the evolving needs of the biologics industry in the United States and around the world.
Company Background
Kemwell Biopharma (search) Pvt Ltd is a leading biologics CDMO headquartered in Bengaluru, India, offering fully integrated services spanning cell-line development, process and analytical development, formulation, drug substance, and sterile drug product manufacturing for both novel biologics and biosimilars (search). With more than 45 years of manufacturing excellence and regulatory accreditations including U.S. FDA, Indian FDA, CDSCO (Central Drugs Standard Control Organization), Malaysia NPRA (PIC/S), and recent Qualified Person (QP) audits, Kemwell partners with global pharmaceutical and biotech innovators to accelerate development and reduce time-to-market for biologics.